Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan BioSciences Completes $19 Million in Financing For Expression Database

NEW YORK, April 17- LifeSpan Biosciences has raised $19 million in a third round of private financing, the company said Tuesday.

LifeSpan of Seattle, plans to use the new funds to automate and enhance its high-throughput gene expression analysis technology, launch new disease and gene family databases, including a cancer database, and fortify its gene research programs.

This round of Series C financing was led by SAIC Venture Capital, and also included Zurich-based Equity4life, current shareholders, and private investors. It brings the company's total capital raised to $37.4 million, following $5.2 million in series A financing raised in 1999, and $13.2 million raised in 2000.

"The size of this round of funding represents a strong endorsement of our molecular pathology approach to the production of genomic information," said Joseph Brown, CEO of LifeSpan, in a statement. "We believe our technology holds promise for significantly accelerating drug discovery and development, and clearly the investment community shares our vision."

In an effort to map disease-associated genes and proteins, LifeSpan has performed gene expression and protein localization analysis on its tissue bank of normal and diseased human tissues. The company is compiling these findings into a comprehensive gene and protein expression database of cell types and tissues, with high-resolution digital images. LifeSpan hopes to provide expression profiles for all 30,000-plus genes.

Currently, LifeSpan markets a subset of this information, a database of G protein-coupled receptors, and has early access arrangements for the GPCR database with a number of pharmaceutical companies, including Bristol-Myers Squibb, Merck, Novartis Research Foundation, and Pfizer. The company hopes to market its full expression database products to pharmaceutical and biotech companies for drug discovery.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.